Leo Pharma receives UK approval for Adtralza
Efforts to receive approvals for Leo Pharma's eczema treatment Adtralza are continuing, and have now been rewarded by permission to launch the drug on the UK market.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
While Leo Pharma awaits news on the fate of Adtralza in the US in the wake of a rejection from the Food and Drug Administration (FDA) earlier in the year, the company has positive news from the United Kingdom.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Leo Pharma starts study of eczema tablet for nettle rash
For subscribers
Utility Therapeutics prepares FDA application
For subscribers
